NASDAQ
No price data available for this timeframe.
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO and MENLO PARK, Calif....
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood pressure and cholesterol Results demonstrate the ad...
SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Wolfe Research Healthcare Conference 2025 on November 19, 2025 Fireside chat at 6:20am ...
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed Sydney Mass Spectrometry is the first facility in ...
SAN DIEGO , Nov. 5, 2025 /PRNewswire/ -- The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban on Illumina, Inc. (NASDAQ: ILMN), which had been in place since March 4, 2025. While the ban will be lifted on November 10,...
Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis GAAP operating margin of 21.0% and non-GAAP operating margin of 24.5% for Q3 2025 GAAP diluted EPS of $0.98 and non-GAAP diluted EPS of $1.3...
At ASHG, an early access customer from the London Health Sciences Center Research Institute will demonstrate the power of the 5-base genome for accelerating resolution of rare disease cases Proprietary 5-base chemistry and novel DRAGEN algorithms ena...
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map variants SAN DIEGO , Oct. 15, 2025 /PRNewswire/ -- Ill...
SAN DIEGO , Oct. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2025 following the close of market on Thursday, October 30, 2025. On the same day, at 1:30 pm Pacific Time (4:30...
New business focuses on developing data assets, software, and AI to fuel life science breakthroughs Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO , Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc....